<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">88204</article-id><article-id pub-id-type="doi">10.7554/eLife.88204</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Transmembrane protein CD69 acts as an S1PR1 agonist</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-305550"><name><surname>Chen</surname><given-names>Hongwen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1065-9808</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-305551"><name><surname>Qin</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-305552"><name><surname>Chou</surname><given-names>Marissa</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-260515"><name><surname>Cyster</surname><given-names>Jason G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4735-9745</contrib-id><email>jason.cyster@ucsf.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-122054"><name><surname>Li</surname><given-names>Xiaochun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0177-0803</contrib-id><email>xiaochun.li@utsouthwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>Department of Molecular Genetics, The University of Texas Southwestern Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Microbiology and Immunology, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Howard Hughes Medical Institute, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>Department of Biophysics, The University of Texas Southwestern Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sohn</surname><given-names>Jungsan</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>11</day><month>04</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e88204</elocation-id><history><date date-type="received" iso-8601-date="2023-04-04"><day>04</day><month>04</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-04-09"><day>09</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2023-02-15"><day>15</day><month>02</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.13.528406"/></event></pub-history><permissions><copyright-statement>© 2023, Chen et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Chen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-88204-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-88204-figures-v2.pdf"/><abstract><p>The activation of Sphingosine-1-phosphate receptor 1 (S1PR1) by S1P promotes lymphocyte egress from lymphoid organs, a process critical for immune surveillance and T cell effector activity. Multiple drugs that inhibit S1PR1 function are in use clinically for the treatment of autoimmune diseases. Cluster of Differentiation 69 (CD69) is an endogenous negative regulator of lymphocyte egress that interacts with S1PR1 in cis to facilitate internalization and degradation of the receptor. The mechanism by which CD69 causes S1PR1 internalization has been unclear. Moreover, although there are numerous class A GPCR structures determined with different small molecule agonists bound, it remains unknown whether a transmembrane protein per se can act as a class A GPCR agonist. Here, we present the cryo-EM structure of CD69-bound S1PR1 coupled to the heterotrimeric G<sub>i</sub> complex. The transmembrane helix (TM) of one protomer of CD69 homodimer contacts the S1PR1-TM4. This interaction allosterically induces the movement of S1PR1-TMs 5–6, directly activating the receptor to engage the heterotrimeric G<sub>i</sub>. Mutations in key residues at the interface affect the interactions between CD69 and S1PR1, as well as reduce the receptor internalization. Thus, our structural findings along with functional analyses demonstrate that CD69 acts in cis as a protein agonist of S1PR1, thereby promoting G<sub>i</sub>-dependent S1PR1 internalization, loss of S1P gradient sensing, and inhibition of lymphocyte egress.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>HEK293</kwd><kwd>WEHI231</kwd><kwd>human</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01 HL160487</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Xiaochun</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 GM135343</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Xiaochun</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000928</institution-id><institution>Welch Foundation</institution></institution-wrap></funding-source><award-id>I-1957</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Xiaochun</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Cyster</surname><given-names>Jason G</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AI040098</award-id><principal-award-recipient><name><surname>Cyster</surname><given-names>Jason G</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Cryo-EM in combination with biochemistry, flow cytometry and fluorescence microscopy reveals the activation of S1PR1 by CD69, a type II membrane protein, in cis to induce receptor internalization and thereby disrupt cellular responsiveness to S1P gradients.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Sphingosine-1-phosphate (S1P) plays an essential role in the immune system by promoting the egress of lymphocytes from lymphoid organs into blood and lymph via a direct interaction with one of its five cognate G protein–coupled receptors, S1PR1 (<xref ref-type="bibr" rid="bib3">Baeyens and Schwab, 2020</xref>; <xref ref-type="bibr" rid="bib7">Cartier and Hla, 2019</xref>; <xref ref-type="bibr" rid="bib11">Cyster and Schwab, 2012</xref>; <xref ref-type="bibr" rid="bib36">Pappu et al., 2007</xref>; <xref ref-type="bibr" rid="bib42">Rosen et al., 2013</xref>; <xref ref-type="bibr" rid="bib47">Spiegel and Milstien, 2003</xref>). After egressing from spleen, lymph nodes, or mucosal lymphoid tissues, T and B lymphocytes travel to other lymphoid organs in a cycle of continual pathogen surveillance. When an infection occurs, there is a temporary shutdown of lymphocyte egress from the responding lymphoid organ(s) and this enables increased accumulation of lymphocytes and enhances the immune response (<xref ref-type="bibr" rid="bib11">Cyster and Schwab, 2012</xref>). Egress shutdown is mediated by type I interferon (IFN) inducing lymphocyte CD69 expression. CD69, a type II transmembrane C-type lectin protein, intrinsically inhibits the function of S1PR1 in T and B cells (<xref ref-type="bibr" rid="bib46">Shiow et al., 2006</xref>). CD69 also regulates T cell egress from the thymus (<xref ref-type="bibr" rid="bib33">Nakayama et al., 2002</xref>; <xref ref-type="bibr" rid="bib58">Zachariah and Cyster, 2010</xref>). A disulfide-bond in the extracellular domain links CD69 as a homodimer (<xref ref-type="bibr" rid="bib61">Ziegler et al., 1994</xref>). Biochemical studies demonstrated that CD69 may associate with S1PR1 through interactions between their transmembrane domains (TMs) to facilitate S1PR1 internalization and degradation (<xref ref-type="bibr" rid="bib4">Bankovich et al., 2010</xref>). Unlike S1P, CD69 has been shown to bind S1PR1 but not the other S1PRs (<xref ref-type="bibr" rid="bib4">Bankovich et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Jenne et al., 2009</xref>; <xref ref-type="bibr" rid="bib46">Shiow et al., 2006</xref>). However, the mechanism of CD69-induced S1PR1 internalization and thus functional inactivation has been unclear.</p><p>Importantly, several S1PR1 modulators (e.g. Fingolimod, also known as FTY720, Siponimod, Ozanimod, and Etrasimod), have been approved for treating the autoimmune diseases multiple sclerosis and ulcerative colitis (<xref ref-type="bibr" rid="bib5">Brinkmann et al., 2010</xref>; <xref ref-type="bibr" rid="bib9">Chun et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Dal Buono et al., 2022</xref>; <xref ref-type="bibr" rid="bib21">Kappos et al., 2010</xref>). These immunosuppressants are believed to act by inhibiting S1PR1 function and thereby preventing autoimmune effector lymphocytes exiting lymphoid organs, blocking the autoimmune attack. Either sphingosine or FTY720 is metabolically catalyzed by two intracellular sphingosine kinases into the phosphorylated form (S1P or FTY720-P) and then exported to the extracellular space via S1P transporters (<xref ref-type="bibr" rid="bib3">Baeyens and Schwab, 2020</xref>; <xref ref-type="bibr" rid="bib48">Spiegel et al., 2019</xref>). There, S1P binds to its receptors for initiation of the signal while FTY720-P activates the S1PR1 but causes a persistent internalization and degradation of S1PR1 to attenuate the signal (<xref ref-type="bibr" rid="bib5">Brinkmann et al., 2010</xref>).</p><p>Recently, cryogenic electron microscopy (cryo-EM) structures of S1PR1 complexed with different small molecule ligands have been determined (<xref ref-type="bibr" rid="bib25">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="bib54">Xu et al., 2022</xref>; <xref ref-type="bibr" rid="bib56">Yu et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>). These findings reveal a mechanism of how S1PR1 engages its endogenous ligand S1P and its modulators to adopt the active conformation for recruiting the heterotrimeric G<sub>i</sub> protein. The previously determined crystal structure of antagonist ML056-bound S1PR1 reveals its inactive state (<xref ref-type="bibr" rid="bib18">Hanson et al., 2012</xref>). However, the molecular mechanism remains unknown of how CD69 binds to S1PR1 to trigger its internalization. Therefore, structural study on the S1PR1-CD69 complex will provide molecular insights into the CD69-mediated functional inhibition of S1PR1 and reveal how a class A GPCR can be regulated by a transmembrane protein modulator. In this manuscript, we determined the structure of CD69-bound S1PR1 coupled to G<sub>αiβ1γ2</sub> heterotrimer by cryo-EM at 3.15 Å resolution. Our findings reveal that TM of CD69 contacts TM4 of S1PR1 to activate the receptor allowing it to engage the α5 helix of G<sub>αi</sub> in the absence of S1P ligand, thereby disrupting the receptor’s egress-promoting function.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>Since serum contains an abundance of lipids including S1P, we expressed human S1PR1 or CD69 in HEK293 cells cultured in a medium with lipid-deficient serum. Then, we purified human S1PR1 protein alone to validate its activation in the presence of S1P using the GTPase-Glo assay (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We then tested the effect on S1PR1 of adding the CD69 homodimer in the absence of S1P. Remarkably, addition of CD69 alone caused a similar amount of G<sub>i</sub> activation as addition of S1P indicating that CD69 functions as a protein agonist of S1PR1 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Overall structure of human CD69-S1PR1-G<sub>i</sub> complex.</title><p>(<bold>A</bold>) S1PR1-induced GTP turnover for G<sub>i1</sub> in the presence of purified CD69 or S1P. Luminescence signals were normalized relative to the condition with G<sub>i1</sub> only. Data are mean ± s.e.m. of three independent experiments. One-way ANOVA with Tukey’s test; ****p&lt;0.0001. Experiments were repeated at least three times with similar results. (<bold>B</bold>) Cryo-EM map of human CD69 bound S1PR1-G<sub>i</sub> complex. (<bold>C</bold>) Cartoon presentation of the complex in the same view and color scheme as shown in (<bold>B</bold>). Slab view of S1PR1 from the extracellular side showing that the orthosteric binding pocket is vacant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Cryo-EM reconstruction of CD69 bound S1PR1-G<sub>i</sub> complex.</title><p>(<bold>A</bold>) Size exclusion column profile of CD69-S1PR1-G<sub>i</sub> complex. Elution fractions of the peak indicated by cyan color were pooled and concentrated for use in grid vitrification. (<bold>B</bold>) Representative micrograph after motion correction. (<bold>C</bold>) Data processing workflow of CD69-S1PR1-G<sub>i</sub> complex. Representative 2D classes are shown. (<bold>D</bold>) FSC curve of the final reconstruction in Post-processing of Relion. (<bold>E</bold>) Local resolution display of the reconstructed map. Local resolution was estimated within Relion. (<bold>F</bold>) Angular distribution of particles used in the final reconstruction of the complex.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Original uncropped SDS-PAGE gels for data in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88204-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Uncropped SDS-PAGE gels for data in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> with the relevant bands labeled.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88204-fig1-figsupp1-data2-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>The cryo-EM density map of CD69-bound S1PR1-G<sub>i</sub> complex.</title><p>(<bold>A</bold>) Representative regions of CD69, S1PR1, and Gα<sub>i1</sub> are shown. (<bold>B</bold>) The cryo-EM density maps of the CD69 residues. (<bold>C</bold>) The cryo-EM density maps of the S1PR1 residues. The density map is drawn by ChimeraX.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Structural comparison between CD69-bound S1PR1 and S1P-bound S1PR1.</title><p>(<bold>A</bold>) Structures of S1PR1 binding with CD69 and S1P. CD69-bound receptor in blue and S1P-bound S1PR1 (PDB code: 7TD3) in cyan. S1P is shown as balls and sticks in yellow. (<bold>B</bold>) The flipping of F161<sup>4.43</sup> of the structures. (<bold>C</bold>) A model of 2:2 CD69-S1PR1 complex with G<sub>i</sub> heterotrimer. The steric clash between the modeled S1PR1 and the N-helix of Gai is indicated by an arrow.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Structures of homodimeric and heterodimeric GPCRs.</title><p>(<bold>A</bold>) Overall structures of G<sub>s</sub>-protein-coupled CGRP receptor with CGRP. (<bold>B</bold>) Overall structures of mGlu2 homodimer. (<bold>C</bold>) mGlu2–mGlu7 heterodimer. (<bold>D</bold>) the class D GPCR Ste2. Transmembrane helices are labeled and PDB codes are shown in parentheses.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig1-figsupp4-v2.tif"/></fig></fig-group><p>To perform structural studies, we mixed lysates from HEK293 cells that independently expressed human CD69 and human S1PR1. The CD69-S1PR1 complex was then incubated with G<sub>αiβ1γ2</sub> heterotrimer and scFv16 (<xref ref-type="bibr" rid="bib27">Maeda et al., 2018</xref>) at 1:1.2:1.4 molar ratio. After gel-filtration purification, the resulting complex was concentrated for cryo-EM analysis (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). We obtained over 1 million particles from ~4000 cryo-EM images. The overall structure of the CD69-bound S1PR1 coupled to heterotrimeric G<sub>i</sub> was determined at 3.15 Å resolution by 293,516 particles (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–F</xref>; <xref ref-type="table" rid="table1">Table 1</xref>). The structure shows that one S1PR1 binds one CD69 homodimer and one G<sub>i</sub> heterotrimer. It also revealed well-defined features for the canonical seven transmembrane helices (7-TMs) of S1PR1, the G<sub>αi</sub> Ras-like domain, the G<sub>β</sub> and G<sub>γ</sub> subunits and scFv16 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). The intracellular loop 3 (ICL3) and the C-terminus of S1PR1 and the intracellular and extracellular domains of CD69 were not found in the cryo-EM map indicating their flexibility in the complex. In contrast, the TMs of the CD69 homodimer were clearly defined in the map owing to their interactions with S1PR1 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>; the interacting TM helix is referred to as CD69-a). Because no lipid was supplemented into the protein during the expression and purification, there is no notable lipid ligand in the 7-TM bundle of S1PR1, which is different from the previous structural discoveries on S1PRs (<xref ref-type="bibr" rid="bib8">Chen et al., 2022</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="bib54">Xu et al., 2022</xref>; <xref ref-type="bibr" rid="bib56">Yu et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">Zhao et al., 2022</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Cryo-EM data collection, processing, and refinement statistics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Structure</th><th align="center" valign="bottom">CD69-S1PR1-Gi-scFv16</th></tr></thead><tbody><tr><td align="left" valign="bottom">PDB</td><td align="center" valign="bottom">8G94</td></tr><tr><td align="left" valign="bottom">EMDB</td><td align="center" valign="bottom">EMD-29861</td></tr><tr><td align="left" valign="bottom"><bold>Data collection/ processing</bold></td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Magnification</td><td align="center" valign="bottom">105,000</td></tr><tr><td align="left" valign="bottom">Voltage (kV)</td><td align="center" valign="bottom">300</td></tr><tr><td align="left" valign="bottom">Pixel size (Å)</td><td align="center" valign="bottom">0.83</td></tr><tr><td align="left" valign="bottom">Defocus range (μm)</td><td align="center" valign="bottom">1.0–2.0</td></tr><tr><td align="left" valign="bottom">Electron exposure (e<sup>-</sup>/Å<sup>2</sup>)</td><td align="center" valign="bottom">60</td></tr><tr><td align="left" valign="bottom">Symmetry imposed</td><td align="center" valign="bottom">C1</td></tr><tr><td align="left" valign="bottom">Initial particles (No.)</td><td align="center" valign="bottom">~1.1 million</td></tr><tr><td align="left" valign="bottom">Final particles (No.)</td><td align="center" valign="bottom">293,516</td></tr><tr><td align="left" valign="bottom">Map resolution (Å)</td><td align="center" valign="bottom">3.14</td></tr><tr><td align="left" valign="bottom">FSC threshold</td><td align="center" valign="bottom">0.143</td></tr><tr><td align="left" valign="bottom">Map resolution range (Å)</td><td align="center" valign="bottom">25–3.0</td></tr><tr><td align="left" valign="bottom"><bold>Refinement</bold></td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Model Resolution (Å)</td><td align="center" valign="bottom">3.3</td></tr><tr><td align="left" valign="bottom">FSC threshold</td><td align="center" valign="bottom">0.5</td></tr><tr><td align="left" valign="bottom">Map sharpening B-factor (Å<sup>2</sup>)</td><td align="center" valign="bottom">–60</td></tr><tr><td align="left" valign="bottom">Model composition</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Non-hydrogen atoms</td><td align="center" valign="bottom">9223</td></tr><tr><td align="left" valign="bottom">Protein residues</td><td align="center" valign="bottom">1187</td></tr><tr><td align="left" valign="bottom">Ligand</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>B</italic>-factors (Å<sup>2</sup>)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Protein</td><td align="center" valign="bottom">98.23</td></tr><tr><td align="left" valign="bottom">R.m.s. deviations</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Bond lengths (Å)</td><td align="center" valign="bottom">0.006</td></tr><tr><td align="left" valign="bottom">Bond angles (°)</td><td align="center" valign="bottom">0.702</td></tr><tr><td align="left" valign="bottom">Validation</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">MolProbity score</td><td align="center" valign="bottom">1.64</td></tr><tr><td align="left" valign="bottom">Clashscore</td><td align="center" valign="bottom">6.49</td></tr><tr><td align="left" valign="bottom">Rotamers outliers (%)</td><td align="center" valign="bottom">0.00</td></tr><tr><td align="left" valign="bottom">Ramachandran plot (%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Favored</td><td align="center" valign="bottom">95.87</td></tr><tr><td align="left" valign="bottom">Allowed</td><td align="center" valign="bottom">4.13</td></tr><tr><td align="left" valign="bottom">Outliers</td><td align="center" valign="bottom">0.00</td></tr></tbody></table></table-wrap><p>Structural comparison shows that the entire complex and the S1P bound S1PR1-G<sub>i</sub> complex share a similar conformation with a root-mean-square deviation (RMSD) of 0.82 Å (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). The receptors in both complexes can be aligned well; however, the F161<sup>4.43</sup> in TM4 presents a notable shift due to CD69 binding (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>). We docked the S1PR1 bound to the other TM of the CD69 homodimer which showed that the modeled receptor would sterically clash with the G<sub>iα</sub> subunit (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C</xref>). This may explain why only one receptor binds one CD69 homodimer in the presence of the heterotrimeric G-protein.</p><p>Receptor activity-modifying protein 1 (RAMP1), a type I transmembrane domain protein, binds the calcitonin receptor-like receptor (CLR) class B GPCR to form the Calcitonin gene-related peptide (CGRP) receptor which is involved in the pathology of migraine (<xref ref-type="bibr" rid="bib43">Russell et al., 2014</xref>). The structure of G<sub>s</sub>-protein coupled CGRP receptor uncovers that TM of RAMP1 interacts with TMs 3–5 of CLR and the extracellular domains of RAMP1 and CLR have extensive interactions (<xref ref-type="bibr" rid="bib24">Liang et al., 2018</xref>; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>). Both CLR and RAMP1 contribute to the engagement of their agonist CGRP. However, in our structure, CD69 acts as an agonist to activate S1PR1 through a direct binding to TM4 of S1PR1 in the absence of a canonical agonist (e.g. S1P or FTY720-P). The extracellular domain of CD69 is completely invisible in the complex and may not interact with the extracellular loops of S1PR1.</p><p>Another type of intramembrane interaction observed for GPCRs is the formation of either homodimers or heterodimers. The metabotropic glutamate receptor 2 (mGlu2), a Class-C GPCR, employs TM4 to maintain its inactive dimeric state or TM6 to assemble as a homodimer in the presence of its agonist (<xref ref-type="bibr" rid="bib14">Du et al., 2021</xref>; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref>). The structure of inactive mGlu2–mGlu7 heterodimer shows that TM5 plays a key role in the complex assembly (<xref ref-type="bibr" rid="bib14">Du et al., 2021</xref>; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4C</xref>). Moreover, TM1 of the class D GPCR Ste2 is responsible for engaging the TM1 of another Ste2 to form a homodimer (<xref ref-type="bibr" rid="bib49">Velazhahan et al., 2021</xref>; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4D</xref>). These findings elucidate that GPCRs could employ distinct TMs to recruit their transmembrane binding partners.</p><p>The TM of one protomer of CD69 homodimer interacts with the TM4 of S1PR1 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The interface area between TMs is about 600 Å<sup>2</sup>. Structural analysis shows that residues V41, V45, V48, V49, T52, I56, I59, A60 of CD69 mediate its extensive interactions with the receptor (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). Residues L160<sup>4.42</sup>, F161<sup>4.43</sup>, I164<sup>4.46</sup>, W168<sup>4.50</sup>, V169<sup>4.51</sup>, L172<sup>4.54</sup>, I173<sup>4.55</sup>, G176<sup>4.58</sup>, I179<sup>4.61</sup> and M180<sup>4.62</sup> of S1PR1-TM4 contribute to the interaction with CD69 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). However, the TM of another CD69 does not have any interactions with the receptor and heterotrimeric G<sub>i</sub> protein (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Further structural comparison with the S1P-bound S1PR1-G<sub>i</sub> complex indicates that the heterotrimeric G<sub>i</sub> proteins in both complexes exhibit a similar state with a RMSD of 0.45 Å. Also, the intracellular regions of the heptahelical domain adopt a similar conformation to accommodate the G<sub>i</sub> proteins. This finding implies that S1P and CD69 stimulate the receptor to engage the heterotrimeric G<sub>i</sub> proteins in an analogous fashion.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The binding interface between CD69 and S1PR1.</title><p>(<bold>A</bold>) and (<bold>B</bold>) Detailed interactions between CD69-a and TM4 of S1PR1. Residues that contribute to complex formation are labeled. CD69 is shown in green and S1PR1 in slate. (<bold>C</bold>) S1PR1-Flag and CD69-StrepII co-immunoprecipitation assay in transfected HEK293 GnTI<sup>-</sup> cells from one experiment that is representative of three. (<bold>D</bold>) Dose-response curves of S1PR1<sub>WT</sub>, S1PR1<sub>V169Y</sub> and S1PR1<sub>M180Y</sub> for the TGFα shedding assay using S1P. Data are mean ± s.d. (n=3). (<bold>E</bold>) S1PR1-induced GTP turnover for G<sub>i1</sub> in the presence of purified wild-type and mutant CD69. Luminescence signals were normalized relative to the condition with G<sub>i1</sub> only. Data are mean ± s.e.m. of three independent experiments. One-way ANOVA with Tukey’s test; ***p&lt;0.001, ****p&lt;0.0001. Experiments in (<bold>C</bold>)-(<bold>E</bold>) were repeated at least twice with similar results. (<bold>F</bold>) Flow cytometric analysis of S1PR1 surface expression on WEHI231 lymphoma cells transduced with S1PR1 and CD69 wild-type and mutant constructs as indicated. From one experiment that is representative of three.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original uncropped western blots for data in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88204-fig2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Uncropped western blots for data in <xref ref-type="fig" rid="fig2">Figure 2</xref> with the relevant bands labeled.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88204-fig2-data2-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Size exclusion column profiles of CD69 wild type and mutants.</title><p>CD69 is a dimer in size exclusion buffer, but partially dissociated to be monomer when resolved in SDS-PAGE gel.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Original uncropped SDS-PAGE gels for data in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88204-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Uncropped SDS-PAGE gels for data in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> with the relevant bands labeled.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88204-fig2-figsupp1-data2-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig2-figsupp1-v2.tif"/></fig></fig-group><p>To validate our structural observations, we performed the co-immunoprecipitation (co-IP) assay using S1PR1 and CD69 variants. Compared to the wild-type S1PR1, two mutants (V169<sup>4.51</sup>Y and M180<sup>4.62</sup>Y) present reduced binding to CD69 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The TGFα shedding assay showed that these two mutants retained normal activity in response to S1P (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). We also tested two CD69 double mutations (V48F/V49F and I56F/I59F) for their association with S1PR1. The co-IP results show that the interaction between S1PR1 and either mutant is considerably attenuated, thus directly supporting the role of CD69-TM in the complex assembly (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Moreover, we have purified CD69(V48F/V49F) and CD69(I56F/I59F) individually and mixed with S1PR1 and G<sub>αiβ1γ2</sub> to conduct a GTPase-Glo assay (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Consistent with the results of our co-IP assays, the activation of G<sub>i</sub> proteins in the presence of either variant was decreased (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). To further validate the physiological role of the CD69-S1PR1-G<sub>i</sub> complex, we tested the two CD69 variants, for their influence on CD69-mediated S1PR1 internalization in WEHI231 B lymphoma cells. In accord with the biochemical data, CD69(V48F/V49F), and CD69(I56F/I59F) were both reduced in their ability to downregulate S1PR1 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>).</p><p>The structures of the S1PR1 complex with its small molecule modulators (including S1P, FTY720-P, BAF312, and ML056) uncover that the TMs 3, 5, 6, and 7 contribute to accommodate the modulators in the orthosteric site (<xref ref-type="bibr" rid="bib18">Hanson et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="bib54">Xu et al., 2022</xref>; <xref ref-type="bibr" rid="bib56">Yu et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>). In contrast, S1PR1 employs its TM4 to associate with CD69 which functions as a protein agonist for triggering receptor activation. Structural comparison with the inactive state of ML056 bound S1PR1 reveals a unique mechanism of CD69-mediated S1PR1 activation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The binding of CD69 induces a 4 Å shift at the intracellular end of TM4 causing the residues C167<sup>4.49</sup>, I170<sup>4.52</sup>, and L174<sup>4.56</sup> in TM4 to face TM3 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). C167<sup>4.49</sup> and I170<sup>4.52</sup> have hydrophobic contacts with the F133<sup>3.41</sup> in TM3, and L174<sup>4.56</sup> pushes the F210<sup>5.47</sup> in TM5 towards the edge of the receptor to form the hydrophobic interactions with W269<sup>6.48</sup> and F273<sup>6.52</sup> in TM6 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). These interactions trigger the notable movement of TM5 and TM6 allowing the opening of intracellular regions to engage the heterotrimeric G<sub>i</sub> proteins (<xref ref-type="fig" rid="fig3">Figure 3A and D</xref>). Residues A137<sup>3.45</sup>, I170<sup>4.52</sup>, L174<sup>4.56</sup>, F210<sup>5.47</sup>, W269<sup>6.48</sup>, and F273<sup>6.52</sup> are conserved among S1PR1, S1PR2 and S1PR3, but not F133<sup>3.41</sup> and C167<sup>4.49</sup>. Remarkably, further comparison shows that the key residues, which are crucial for the S1P binding and receptor activation, present similar conformations in the structures of S1P-bound S1PR1 and CD69-bound S1PR1, although S1P and CD69 have different structural natures and completely distinct binding sites in the receptor (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Comparison between CD69-bound S1PR1 and ML056- or S1P-bound S1PR1.</title><p>(<bold>A</bold>) Overall structures of S1PR1 binding with CD69 and ML056. The CD69-bound S1PR1 structure was aligned to ML056-bound inactive S1PR1 (PDB code: 3V2Y). ML056-bound receptor is shown in brown, CD69-bound receptor in blue, and the TM of CD69 in green. The same color scheme is used (<bold>C</bold>) and (<bold>D</bold>). (<bold>B</bold>) The movements of TM4 and TM6 of CD69-bound S1PR1 compared with ML056-bound inactive S1PR1. (<bold>C</bold>) Residues involved in the TM movements. (<bold>D</bold>) TM6 movement around W269<sup>6.48</sup> and F273<sup>6.52</sup>. (<bold>E</bold>) Comparison between CD69-bound S1PR1 and S1P-bound S1PR1 (PDB code: 7TD3). Residues in the ligand binding pocket are shown. CD69-bound receptor in blue and S1P-bound S1PR1 in cyan. S1P is shown as balls and sticks in yellow.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>S1PR1 specificity for CD69 binding.</title><p>(<bold>A</bold>) Co-immunoprecipitation assay in transfected HEK293 GnTI<sup>-</sup> cells from one experiment that is representative of three. (<bold>B</bold>) Sequence alignment of S1PR homologues. The different residues among S1PRs which are crucial for CD69 binding are indicated by blue stars.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Original uncropped western blots for data in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88204-fig3-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Uncropped western blots for data in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> with the relevant bands labeled.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88204-fig3-figsupp1-data2-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Structures of GPCRs with their positive allosteric modulators.</title><p>(<bold>A</bold>) Structure of GABA<sub>B</sub>. The BHFF, a positive allosteric modulator (PAM) of GABA<sub>B</sub>, is shown as magenta sticks. (<bold>B</bold>) Structure of CB1. The ZCZ011, a PAM of CB1, is shown as magenta sticks. (<bold>C</bold>) Structure of A<sub>1</sub>R. The MIPS521, a PAM of A<sub>1</sub>R, is shown as magenta sticks. Transmembrane helices for PAM binding are labeled and PDB codes are shown in parentheses.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig3-figsupp2-v2.tif"/></fig></fig-group><p>To date, five S1PRs have been identified. These receptors have different tissue distributions, and they also function via distinct kinds of G proteins (including G<sub>i</sub>, G<sub>q</sub>, and G<sub>12/13</sub>) (<xref ref-type="bibr" rid="bib7">Cartier and Hla, 2019</xref>). Previous work showed that CD69 specifically binds to S1PR1, and it does not associate with S1PR2, S1PR3 or S1PR5 (<xref ref-type="bibr" rid="bib4">Bankovich et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Jenne et al., 2009</xref>; <xref ref-type="bibr" rid="bib46">Shiow et al., 2006</xref>). To dissect the binding specificity of CD69, we carried out the co-IP assays to show a very weak interaction between S1PR2 and CD69 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Although the sequence homology among five S1PRs is high, residues L157<sup>4.51</sup> and L168<sup>4.62</sup> in S1PR2-TM4 are not conserved with those in S1PR1 and are determinants for specific recognition of CD69 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). We speculated that converting these two residues to those in S1PR1 may prompt the interaction between S1PR2 variant and CD69. Our co-IP result clearly shows that S1PR2(L157<sup>4.51</sup>V/L168<sup>4.62</sup>M) could interact with CD69 albeit the interactions are weaker than that between S1PR1 and CD69 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). This finding further demonstrates the essential role of S1PR1-TM4 in the CD69-mediated S1PR1 signaling.</p><p>All the known small molecule S1PR1 agonists or antagonists bind to the orthosteric site in the heptahelical domain (<xref ref-type="bibr" rid="bib18">Hanson et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="bib54">Xu et al., 2022</xref>; <xref ref-type="bibr" rid="bib56">Yu et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Yuan et al., 2021</xref>). Interestingly, the CD69 binding site is akin to that of the allosteric agents which attach to receptors (<xref ref-type="bibr" rid="bib13">Draper-Joyce et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Mao et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Yang et al., 2022</xref>), although the nature of these agents and CD69 is quite different. The diversity of the allosteric modulator binding sites in GPCRs has been revealed by numerous structures (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). When the orthosteric site is occupied, the positive allosteric modulator attaches to the receptor and then increases agonist affinity and/or efficacy. CD69 binds to the edge of S1PR1, but it acts as a protein agonist to directly activate the receptor in the absence of any agonists in the orthosteric site. Thus, our finding suggests CD69 is different from other S1PR1 agonists in that it functions via a direct binding to the edge of the receptor.</p><p>It remains unknown whether the antagonist of S1PR1 bound to the 7-TMs will affect the CD69-mediated regulation of S1PR1. We co-transfected S1PR1-GFP and CD69-mCherry into HEK293 cells in a lipid depleted medium. After 24 hr, the fluorescence images show that substantial receptors (~80%) have been internalized with CD69. However, when we added the Ex26, a potent S1PR1 antagonist (<xref ref-type="bibr" rid="bib6">Cahalan et al., 2013</xref>), into the cells 6 hr after transfection, the images show that just ~50% receptors have been internalized (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). This finding indicates that the CD69-mediated S1PR1 activation could be reversed when the 7-TMs pocket is preoccupied by an antagonist.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>CD69 induced S1PR1 internalization.</title><p>(<bold>A</bold>) HEK293 cells were treated with 2 μM Ex26 or vehicle for 12 hr and imaged using confocal microscopy. Scale bar, 10 μm. (<bold>B</bold>) Quantification of intracellular S1PR1 of the cells in (<bold>A</bold>). (<bold>C</bold>) HEK293 cells were treated with 20 μM Barbadin for 12 hr and imaged for analysis. Scale bar, 10 μm. (<bold>D</bold>) Quantification of intracellular S1PR1 of the cells in (<bold>C</bold>). (<bold>E</bold>) HEK293 cells were treated with 200 ng/ml pertussis toxin (PTX) for 12 hr and imaged for analysis. Scale bar, 10 μm. (<bold>F</bold>) Quantification of intracellular S1PR1 of the cells in (<bold>E</bold>). Data are mean ± s.e.m. Two-sided Welch’s t-test; ns, not significant, **p&lt;0.01, ****p&lt;0.0001. All experiments were repeated at least three times with similar results.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Barbadin alters the FTY720-P mediated S1PR1 internalization.</title><p>(<bold>A</bold>) HEK293 cells were treated with 20 mM Barbadin for 2 hr followed by vehicle- or FTY720-P-treatment for 1 hr and imaged using confocal microscopy. Scale bar, 10 mm. (<bold>B</bold>) Quantification of intracellular S1PR1 of the cells in (<bold>A</bold>). Data are mean ± s.e.m. Two-sided Welch’s t-test; ****p&lt;0.0001. Experiments were repeated at least twice with similar results.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>S1PR1-induced GTP turnover for G<sub>i1</sub> in the presence of purified CD69 and S1P.</title><p>Luminescence signals were normalized relative to the condition with G<sub>i1</sub> only. Data are mean ± s.e.m. of three independent experiments. Two-sided Student’s t-test; ns, not significant. Experiments were repeated at least twice with similar results.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-fig4-figsupp2-v2.tif"/></fig></fig-group><p>It has been known that S1P, FTY720-P and CD69, could promote the internalization of S1PR1. However, the mechanisms of S1P- and FTY720-P-mediated internalization appear to be different. While both S1P and FTY720-P activate G<sub>i</sub>-signaling, FTY720-P is considered as a β-arrestin-biased agonist, and FTY720-P-induced S1PR1 internalization is β-arrestin-dependent (<xref ref-type="bibr" rid="bib35">Oo et al., 2007</xref>; <xref ref-type="bibr" rid="bib54">Xu et al., 2022</xref>). The pathway of S1P-mediated internalization can be β-arrestin-dependent or independent (<xref ref-type="bibr" rid="bib16">Galvani et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Reeves et al., 2016</xref>). To test the mechanism of how CD69 induces the receptor internalization, we performed a fluorescence imaging assay to check the internalization of S1PR1 in the presence of either G<sub>i</sub> inhibitor Pertussis toxin (PTX) or β-arrestin inhibitor Barbadin. The plasmids encoding S1PR1-GFP and CD69-mCherry were co-transfected into HEK293 cells in a lipid depleted medium. After 6 hr, we added PTX or Barbadin. On day 2, we calculated the fraction of internalized S1PR1 in each group by fluorescence imaging. The results show that Barbadin does not interfere with CD69-induced receptor internalization (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>), but PTX could prevent half of the receptors from internalization (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>). Our finding also supports that Barbadin was effective in reducing FTY70-P-induced S1PR1 internalization (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Thus, CD69 agonism of S1PR1 induces G<sub>i</sub>-dependent internalization of the complex.</p></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our studies provide a model for understanding how the lymphocyte activation marker CD69 controls lymphocyte egress and thus augments adaptive immunity. As an immediate early gene, CD69 is strongly transcriptionally induced in lymphocytes within an hour of exposure to type I IFN, toll-like receptor (TLR) ligands, or antigen receptor engagement (<xref ref-type="bibr" rid="bib17">Grigorova et al., 2010</xref>; <xref ref-type="bibr" rid="bib46">Shiow et al., 2006</xref>; <xref ref-type="bibr" rid="bib61">Ziegler et al., 1994</xref>). Following induction, CD69 protein engages S1PR1 as an agonist, causing S1PR1 internalization and loss of the ability to sense S1P gradients. We speculate that even prior to internalization, CD69 disrupts S1PR1’s egress promoting function by acting as a high concentration agonist and thus making the receptor ‘blind’ to S1P distribution. Consistently, our functional analysis reveals that CD69 could not synergize with S1P to trigger S1PR1 activation (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><p>Previous work has shown the critical importance of correctly distributed S1P and thus correctly localized S1PR1 activation for effective lymphocyte egress (<xref ref-type="bibr" rid="bib45">Schwab et al., 2005</xref>). As well as promoting egress, S1PR1, transmits signals needed for maintaining T cell survival (<xref ref-type="bibr" rid="bib29">Mendoza et al., 2017</xref>) and CD69 has been implicated in transmitting signals that influence T cell differentiation (<xref ref-type="bibr" rid="bib10">Cibrián and Sánchez-Madrid, 2017</xref>; <xref ref-type="bibr" rid="bib22">Kimura et al., 2017</xref>). Whether the CD69-S1PR1 complex contributes to these signals before undergoing degradation merits further study. GRK2 (<xref ref-type="bibr" rid="bib2">Arnon et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Oo et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Watterson et al., 2002</xref>) and dynamin (<xref ref-type="bibr" rid="bib53">Willinger et al., 2014</xref>) participate in S1PR1 internalization in response to S1P. In accord with these factors possibly having a role in CD69-mediated S1PR1 internalization, they have been shown to promote internalization of some receptors independently of β-arrestins (<xref ref-type="bibr" rid="bib30">Moo et al., 2021</xref>). The selectivity of CD69 for S1PR1 is important for allowing activated CD69<sup>+</sup> lymphocytes and natural killer cells to employ other S1PRs, such as S1PR2 and S1PR5, to carry out functions without interruption by CD69 (<xref ref-type="bibr" rid="bib20">Jenne et al., 2009</xref>; <xref ref-type="bibr" rid="bib23">Laidlaw et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Moriyama et al., 2014</xref>). The lack of conservation of key residues that mediate the S1PR1-CD69 interaction in TM4 of S1PR2, S1PR5 and the other S1PRs provides an explanation for this selectivity (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). In summary, we provide the first example of GPCR activation by interaction in cis with a transmembrane ligand and thereby explain the mechanism of lymphocyte egress shutdown. The structure also offers insights that may enable introduction of transcriptionally inducible GPCR switches into CAR-T cells and other engineered cell types.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Constructs</title><p>For expression and purification, the wild-type human S1PR1 (a.a.1–347, UniProt: P21453) and CD69 (full-length, UniProt: Q07108) were separately cloned into pEZT-BM vector (<xref ref-type="bibr" rid="bib31">Morales-Perez et al., 2016</xref>) with a C-terminal Flag tag and StrepII tag, respectively. Plasmids of Gα<sub>i1</sub>, Gβ<sub>1</sub>/Gγ<sub>2</sub> and scFv16 are kind gifts from Brian Kobilka (Stanford University). For co-immunoprecipitation assay, the full-length wild-type human S1PR1 fused with a C-terminal Flag tag and CD69 fused with a C-terminal StrepII tag, were separately cloned into pCAGGS vector (<xref ref-type="bibr" rid="bib34">Niwa et al., 1991</xref>) with modified multiple cloning sites. For fluorescence microscopy, the plasmids pCAGGS-S1PR1-Flag-GFP and pCAGGS-CD69-StrepII-mCherry were constructed.</p></sec><sec id="s4-2"><title>Protein expression and purification</title><p>S1PR1-Flag and CD69-StrepII were separately expressed using baculovirus-mediated transduction of mammalian HEK293S GnTI<sup>−</sup> cells (ATCC CRL-3022) in a medium containing FreeStyle 293 (Gibco Cat# 12338018) supplemented with 2% charcoal-dextran stripped fetal bovine serum (Gibco Cat# 12676029), penicillin (100 U/mL), and streptomycin (100 μg/mL) (Corning Cat# 30–002 CI). Baculoviruses were generated in Sf9 cells, and P2 virus was used to infect HEK293S GnTI<sup>−</sup> cells at 37 °C. At 8 hr after infection, sodium butyrate at a final concentration of 10 mM was added to the culture. After further incubation for 64 hr at 30 °C, cells expressing S1PR1-Flag and CD69-StrepII were mixed together and resuspended in buffer A (20 mM HEPES, pH 7.5, 150 mM NaCl) supplemented with protease inhibitors and then homogenized by sonication. The protein was solubilized with 1% LMNG (lauryl maltose neopentyl glycol) /0.1% CHS (cholesteryl hemisuccinate) for 1 hr at 4 °C. Insoluble material was removed by centrifugation at 40,000 <italic>g</italic>, 4 °C for 30 min, and the supernatant was incubated with Strep-Tactin XT resin (IBA Cat# 2-5030-025) for batch binding. The resin was washed with 20 column volumes (CV) of buffer A containing 0.01% LMNG/0.001% CHS. The protein complex was eluted with 6 CVs of buffer A containing 0.01% LMNG/0.001% CHS and 50 mM biotin, followed by a second affinity purification by anti-Flag M2 resin (Sigma-Aldrich). The excessive CD69-StrepII was washed off with 20 CVs of buffer A containing 0.01% LMNG/0.001% CHS, and the complex was eluted with 5 CVs of 3×Flag peptide (0.1 mg/ml; ApexBio). The eluted protein was further purified by gel filtration using a Superose 6 Increase 10/300 GL column (Cytiva) with 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.001% L-MNG/0.0001% CHS, and 0.0025% glyco-diosgenin (GDN). The peak fractions were collected for complex assembly.</p><p>To assemble the CD69-S1PR1-G<sub>i</sub>-scFv16 complex, purified CD69-S1PR1 was mixed with the Gi heterotrimer at a 1:1.2 molar ratio. This mixture was incubated on ice for 1 hr, followed by the addition of apyrase to catalyze the hydrolysis of unbound GDP on ice for 1 hr. Then, scFv16 was added at a 1.4:1 molar ratio (scFv16: CD69-S1PR1) followed by 30 min incubation on ice. The mixture was diluted 10-fold by gel filtration column buffer. To remove excess Gi and scFv16 proteins, the mixture was purified by anti-Flag M2 affinity chromatography. The complex was eluted and concentrated using an Amicon Ultra Centrifugal Filter (molecular weight cutoff 100 kDa). The complex was further purified by gel filtration (Superose 6 Increase 10/300 GL) with buffer 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.001% L-MNG/0.0001% CHS, and 0.0025% GDN. Peak fractions consisting of CD69-S1PR1-G<sub>i</sub> complex were concentrated to ~10–12 mg/ml for cryo-EM studies.</p></sec><sec id="s4-3"><title>Cryo-EM sample preparation and data acquisition</title><p>The freshly purified CD69-S1PR1-G<sub>i</sub>-scFv16 complex was added to Quantifoil R1.2/1.3 400-mesh Au holey carbon grids (Quantifoil), blotted using a Vitrobot Mark IV (FEI), and vitrified in liquid ethane. The grids were imaged in a 300-kV Titan Krios (FEI) with a Gatan K3 Summit direct electron detector. Data were collected in super-resolution mode at a pixel size of 0.415 Å with a dose rate of 23 electrons per physical pixel per second. Images were recorded for 5 s exposures in 50 subframes with a total dose of 60 electrons per Å<sup>2</sup>.</p></sec><sec id="s4-4"><title>Imaging processing and 3D reconstruction</title><p>A total of 4,239 dose-fractionated image stacks of CD69-S1PR1-G<sub>i</sub> complex were collected and subjected to single particle analysis using RELION-3.1 (<xref ref-type="bibr" rid="bib62">Zivanov et al., 2018</xref>) and cryoSPARC v3.3 (<xref ref-type="bibr" rid="bib39">Punjani et al., 2017</xref>). MotionCor2 (<xref ref-type="bibr" rid="bib60">Zheng et al., 2017</xref>) was used for motion correction and dose weighting, CTFFIND-4.1 <xref ref-type="bibr" rid="bib41">Rohou and Grigorieff, 2015</xref> for contrast transfer function (CTF) estimation, and crYOLO <xref ref-type="bibr" rid="bib50">Wagner et al., 2019</xref> for particle picking with a general model. A total of 1,113,446 particles were extracted with a pixel size of 1.66 Å in RELION and imported to cryoSPARC. The imported particles were subjected to ab initio model reconstruction and several rounds of alternating 2D classification and heterogeneous refinement. Then 336,669 particles from the best class were re-extracted at full pixel size (0.83 Å) in RELION and imported to cryoSPARC again. Two heterogeneous refinements were performed in parallel and the resulting particles from the two best classes were combined with duplicates removed. These 293,516 particles were subjected to CTF refinement and Bayesian polishing followed by masked 3D auto refinement. RELION postprocessing was used for sharpening of the final map.</p></sec><sec id="s4-5"><title>Model construction and refinement</title><p>The cryo-EM structure of the S1PR1-G<sub>i</sub> bound to S1P (PDB: 7TD3) (<xref ref-type="bibr" rid="bib25">Liu et al., 2022</xref>) was used as initial models and manually docked into cryo-EM density map with UCSF Chimera-1.15 (<xref ref-type="bibr" rid="bib37">Pettersen et al., 2004</xref>). The transmembrane helix of CD69 was manually built using Coot-0.9.6 (<xref ref-type="bibr" rid="bib15">Emsley and Cowtan, 2004</xref>). Due to the limited local resolution, the TM of CD69-b was built as polyalanine. The resulting model was subjected to iterative rounds of manual adjustment and rebuilding in Coot and real-space refinement in Phenix-1.16 (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>). MolProbity (<xref ref-type="bibr" rid="bib52">Williams et al., 2018</xref>) was used to validate the geometries of the model. Structural figures were generated using UCSF Chimera-1.15, ChimeraX-1.5 (<xref ref-type="bibr" rid="bib38">Pettersen et al., 2021</xref>), and PyMOL-2.3 (<ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">https://pymol.org/2/</ext-link>).</p></sec><sec id="s4-6"><title>GTP turnover assay</title><p>GTP turnover was analyzed using GTPase-Glo Assay kit (Promega Cat# V7681). Briefly, the purified S1PR1 was first incubated with purified CD69 and/or S1P followed by mixing with isolated Gi protein in an assay buffer containing 20 mM HEPES, pH7.5, 150 mM NaCl, 0.01% LMNG/0.001% CHS, 10 mM MgCl<sub>2</sub>, 100 μM TCEP, 10 μM GDP and 5 μM GTP. After incubation for 60 min, the reconstituted GTPase-Glo reagent was added to the sample and incubated for 30 min at room temperature. The amount of remaining GTP was assessed by measuring luminescence after adding and incubation with the detection reagent for 10 min at room temperature. The luminescence signal was normalized in each case to that of G-protein alone. Data were analyzed using GraphPad Prism 9.</p></sec><sec id="s4-7"><title>Co-immunoprecipitation and immunoblotting assay</title><p>HEK293 GnTI<sup>-</sup> cells were transfected with plasmids encoding CD69-StrepII and S1PR1-Flag using FuGene 6 transfection reagent in 60 mm dishes. Forty-eight hr post transfection, cells were harvested and whole cell lysates were prepared using IP lysis buffer (Thermo Scientific) supplemented with protease inhibitor cocktail (Roche). Lysates were cleared by centrifuging at 20,000 <italic>g</italic> for 15 min at 4 °C. Supernatants were incubated with anti-Flag M2 affinity beads (MilliporeSigma) with end-over-end rotation for 2 h at 4 °C. Beads were washed three times with lysis buffer for 5 min per wash with end-over-end rotation at 4 °C. Proteins were eluted from beads with lysis buffer supplemented with 0.4 mg/ml 3×Flag peptide. Protein samples were loaded Bolt 4–12% Bis-Tris plus gels (Invitrogen) and transferred to TransBlot Turbo nitrocellulose membranes (Bio-Rad). Membranes were blocked for 1 hr at room temperature with 5% milk in PBS with 0.05% Tween 20 (PBST) followed by primary antibody incubation, three-times wash, secondary antibody incubation, and three-times wash again. Membranes were developed for 2 min at room temperature using SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Scientific) and then imaged using the LI-COR Odyssey Fc imaging system. The following primary antibodies were used: Tubulin (D3U1W), Cell Signaling Cat# 86298 (1:3000 dilution); Flag tag (FLA-1), MBL International Cat# M185-3L (1:3000 dilution); StrepII tag, IBA GmbH Cat# 2-1507-001 (1:2000 dilution). Anti-mouse IgG HRP-linked secondary antibody (Cell Signaling Cat# 7076) was used for chemiluminescent detection (1:3000 dilution).</p></sec><sec id="s4-8"><title>TGFα shedding assay</title><p>The agonist activity of S1P for the mutant S1PR1s was determined by the TGFα shedding assays (<xref ref-type="bibr" rid="bib19">Inoue et al., 2012</xref>). Briefly, three pCAGGS plasmids encoding the human full-length S1PR1 variant (empty vector as negative control), the chimeric G<sub>αq/i1</sub> subunit and alkaline phosphatase-fused TGFα (AP-TGFα) were co-transfected into HEK293 cells using FuGene 6 transfection reagent in a 12-well plate. After 24 hr, the transfected cells were collected by trypsinization, washed with phosphate-buffered saline (PBS), and resuspended in Hanks’ balanced salt solution (HBSS) with 5 mM HEPES (pH 7.4). Then, the cells were seeded into a 96-well culture plate and treated with S1P, which was serially diluted in HEPES-containing HBSS with 0.01% fatty acid–free bovine serum albumin. After incubation with S1P, the cell plate was spun, and conditioned media was transferred to an empty 96-well plate. AP reaction solution (120 mM Tris-HCl, pH 9.5, 40 mM NaCl, 10 mM MgCl<sub>2</sub>, and 10 mM p-nitrophenyl phosphate) was added into the cell plates and the conditioned media plates. The absorbance at 405 nm was measured using a microplate reader (Synergy Neo2, BioTek) before and after 2 hr incubation at 37 °C. Ligand-induced AP-TGFα release was calculated as described previously (<xref ref-type="bibr" rid="bib19">Inoue et al., 2012</xref>). AP-TGFα release signal of empty vector-transfected cells were subtracted from that of S1PR1 cells at the corresponding S1P concentration points. Then, the vehicle-treated AP-TGFα release signal was set as a baseline and ligand-induced AP-TGFα release signals were fitted to a four-parameter sigmoidal concentration–response curve using GraphPad Prism 9 software.</p></sec><sec id="s4-9"><title>Fluorescence microscopy</title><p>HEK293 cells were plated in 35 mm glass bottom dishes (Cellvis Cat# D35141.5N) followed by transfection with S1PR1-GFP and/or CD69-mCherry using FuGene 6 reagent on the next day. Twenty-four hr post transfection, the cells were stained with Hoechst 33342 reagent (Thermo Fisher Cat# R37605) and fluorescence images were acquired using a Zeiss LSM 800 microscope system with ZEN imaging software (Zeiss).</p><p>For fluorescence quantification of intracellular S1PR1 and CD69, outside and inside of plasma membrane were circled manually in Fiji software (<xref ref-type="bibr" rid="bib44">Schindelin et al., 2012</xref>). The fluorescence intensities in each circle were measured and regarded as whole-cell and intracellular fluorescence intensity, respectively. The intracellular fluorescence intensity was normalized to its corresponding whole-cell fluorescence intensity. For each data point, ~30 cells were randomly selected for quantification. The data shown in the figures are representative of two or more independent experiments.</p></sec><sec id="s4-10"><title>WEHI231 cell retroviral transduction</title><p>WEHI231 B lymphoma cells were co-transduced with retroviral constructs encoding OX56 N-terminal tagged human S1PR1 containing an IRES-hCD4 reporter and either empty vector or constructs encoding wildtype, V48F/V49F or I56F/I59F human CD69 and an IRES-GFP reporter using methods previously described (<xref ref-type="bibr" rid="bib26">Lu et al., 2019</xref>). After 3–5 days, the cells were harvested and rested for 20 min at 37 °C in PBS without serum, then stained to detect OX56, CD69, and hCD4. OX56 (S1PR1) staining on hCD4 +GFP + CD69 + cells were plotted.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-88204-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The 3D cryo-EM density maps have been deposited in the Electron Microscopy Data Bank under the accession number EMD-29861. Atomic coordinates for the atomic model have been deposited in the Protein Data Bank under the accession number 8G94. All other data needed to evaluate the conclusions in the paper are present in the paper and/or the supplementary materials.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Structure of CD69-bound S1PR1 coupled to heterotrimeric Gi</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/8G94">8G94</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Structure of CD69-bound S1PR1 coupled to heterotrimeric Gi</data-title><source>EMBD</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/emdb/EMD-29861">EMD-29861</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The data were collected at the UT Southwestern Medical Center Cryo-EM Facility (funded in part by the CPRIT Core Facility Support Award RP170644). We thank L Beatty, L Esparza, and Y Xu for technical support. This work was supported by NIH P01 HL160487, R01 GM135343, and Welch Foundation (I-1957) (to XL) and R01 AI040098 (to JGC). JGC is an investigator of Howard Hughes Medical Institute. This article is subject to HHMI’s Open Access to Publications policy. HHMI lab heads have previously granted a nonexclusive CC BY 4.0 license to the public and a sublicensable license to HHMI in their research articles. Pursuant to those licenses, the author-accepted manuscript of this article can be made freely available under a CC BY 4.0 license immediately upon publication.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Hung</surname><given-names>L-W</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>R</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Zwart</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnon</surname><given-names>TI</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Lo</surname><given-names>C</given-names></name><name><surname>Pham</surname><given-names>T</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Coughlin</surname><given-names>S</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood</article-title><source>Science</source><volume>333</volume><fpage>1898</fpage><lpage>1903</lpage><pub-id pub-id-type="doi">10.1126/science.1208248</pub-id><pub-id pub-id-type="pmid">21960637</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baeyens</surname><given-names>AAL</given-names></name><name><surname>Schwab</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Finding a way out: S1P signaling and immune cell migration</article-title><source>Annual Review of Immunology</source><volume>38</volume><fpage>759</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-081519-083952</pub-id><pub-id pub-id-type="pmid">32340572</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bankovich</surname><given-names>AJ</given-names></name><name><surname>Shiow</surname><given-names>LR</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>22328</fpage><lpage>22337</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.123299</pub-id><pub-id pub-id-type="pmid">20463015</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinkmann</surname><given-names>V</given-names></name><name><surname>Billich</surname><given-names>A</given-names></name><name><surname>Baumruker</surname><given-names>T</given-names></name><name><surname>Heining</surname><given-names>P</given-names></name><name><surname>Schmouder</surname><given-names>R</given-names></name><name><surname>Francis</surname><given-names>G</given-names></name><name><surname>Aradhye</surname><given-names>S</given-names></name><name><surname>Burtin</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis</article-title><source>Nature Reviews. Drug Discovery</source><volume>9</volume><fpage>883</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1038/nrd3248</pub-id><pub-id pub-id-type="pmid">21031003</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cahalan</surname><given-names>SM</given-names></name><name><surname>Gonzalez-Cabrera</surname><given-names>PJ</given-names></name><name><surname>Nguyen</surname><given-names>N</given-names></name><name><surname>Guerrero</surname><given-names>M</given-names></name><name><surname>Cisar</surname><given-names>EAG</given-names></name><name><surname>Leaf</surname><given-names>NB</given-names></name><name><surname>Brown</surname><given-names>SJ</given-names></name><name><surname>Roberts</surname><given-names>E</given-names></name><name><surname>Rosen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist</article-title><source>Molecular Pharmacology</source><volume>83</volume><fpage>316</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1124/mol.112.082958</pub-id><pub-id pub-id-type="pmid">23204443</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartier</surname><given-names>A</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sphingosine 1-phosphate: lipid signaling in pathology and therapy</article-title><source>Science</source><volume>366</volume><elocation-id>eaar5551</elocation-id><pub-id pub-id-type="doi">10.1126/science.aar5551</pub-id><pub-id pub-id-type="pmid">31624181</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structure of S1PR2-heterotrimeric G(13) signaling complex</article-title><source>Science Advances</source><volume>8</volume><elocation-id>eabn0067</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abn0067</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>J</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Hunter</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects</article-title><source>Drugs</source><volume>81</volume><fpage>207</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1007/s40265-020-01431-8</pub-id><pub-id pub-id-type="pmid">33289881</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cibrián</surname><given-names>D</given-names></name><name><surname>Sánchez-Madrid</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CD69: from activation marker to metabolic gatekeeper</article-title><source>European Journal of Immunology</source><volume>47</volume><fpage>946</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1002/eji.201646837</pub-id><pub-id pub-id-type="pmid">28475283</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Schwab</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</article-title><source>Annual Review of Immunology</source><volume>30</volume><fpage>69</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-075011</pub-id><pub-id pub-id-type="pmid">22149932</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dal Buono</surname><given-names>A</given-names></name><name><surname>Gabbiadini</surname><given-names>R</given-names></name><name><surname>Alfarone</surname><given-names>L</given-names></name><name><surname>Solitano</surname><given-names>V</given-names></name><name><surname>Repici</surname><given-names>A</given-names></name><name><surname>Vetrano</surname><given-names>S</given-names></name><name><surname>Spinelli</surname><given-names>A</given-names></name><name><surname>Armuzzi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sphingosine 1-phosphate modulation in inflammatory bowel diseases: keeping lymphocytes out of the intestine</article-title><source>Biomedicines</source><volume>10</volume><elocation-id>1735</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10071735</pub-id><pub-id pub-id-type="pmid">35885040</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper-Joyce</surname><given-names>CJ</given-names></name><name><surname>Bhola</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Bhattarai</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>ATN</given-names></name><name><surname>Cowie-Kent</surname><given-names>I</given-names></name><name><surname>O’Sullivan</surname><given-names>K</given-names></name><name><surname>Chia</surname><given-names>LY</given-names></name><name><surname>Venugopal</surname><given-names>H</given-names></name><name><surname>Valant</surname><given-names>C</given-names></name><name><surname>Thal</surname><given-names>DM</given-names></name><name><surname>Wootten</surname><given-names>D</given-names></name><name><surname>Panel</surname><given-names>N</given-names></name><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Christie</surname><given-names>MJ</given-names></name><name><surname>White</surname><given-names>PJ</given-names></name><name><surname>Scammells</surname><given-names>P</given-names></name><name><surname>May</surname><given-names>LT</given-names></name><name><surname>Sexton</surname><given-names>PM</given-names></name><name><surname>Danev</surname><given-names>R</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Glukhova</surname><given-names>A</given-names></name><name><surname>Imlach</surname><given-names>WL</given-names></name><name><surname>Christopoulos</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Positive allosteric mechanisms of adenosine A<sub>1</sub> receptor-mediated analgesia</article-title><source>Nature</source><volume>597</volume><fpage>571</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03897-2</pub-id><pub-id pub-id-type="pmid">34497422</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Tai</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Pin</surname><given-names>J-P</given-names></name><name><surname>Rondard</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structures of human mGlu2 and mGlu7 homo- and heterodimers</article-title><source>Nature</source><volume>594</volume><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03641-w</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>60</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id><pub-id pub-id-type="pmid">15572765</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvani</surname><given-names>S</given-names></name><name><surname>Sanson</surname><given-names>M</given-names></name><name><surname>Blaho</surname><given-names>VA</given-names></name><name><surname>Swendeman</surname><given-names>SL</given-names></name><name><surname>Obinata</surname><given-names>H</given-names></name><name><surname>Conger</surname><given-names>H</given-names></name><name><surname>Dahlbäck</surname><given-names>B</given-names></name><name><surname>Kono</surname><given-names>M</given-names></name><name><surname>Proia</surname><given-names>RL</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra79</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaa2581</pub-id><pub-id pub-id-type="pmid">26268607</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigorova</surname><given-names>IL</given-names></name><name><surname>Panteleev</surname><given-names>M</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Lymph node cortical sinus organization and relationship to lymphocyte egress dynamics and antigen exposure</article-title><source>PNAS</source><volume>107</volume><fpage>20447</fpage><lpage>20452</lpage><pub-id pub-id-type="doi">10.1073/pnas.1009968107</pub-id><pub-id pub-id-type="pmid">21059923</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>MA</given-names></name><name><surname>Roth</surname><given-names>CB</given-names></name><name><surname>Jo</surname><given-names>E</given-names></name><name><surname>Griffith</surname><given-names>MT</given-names></name><name><surname>Scott</surname><given-names>FL</given-names></name><name><surname>Reinhart</surname><given-names>G</given-names></name><name><surname>Desale</surname><given-names>H</given-names></name><name><surname>Clemons</surname><given-names>B</given-names></name><name><surname>Cahalan</surname><given-names>SM</given-names></name><name><surname>Schuerer</surname><given-names>SC</given-names></name><name><surname>Sanna</surname><given-names>MG</given-names></name><name><surname>Han</surname><given-names>GW</given-names></name><name><surname>Kuhn</surname><given-names>P</given-names></name><name><surname>Rosen</surname><given-names>H</given-names></name><name><surname>Stevens</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Crystal structure of a lipid G protein-coupled receptor</article-title><source>Science</source><volume>335</volume><fpage>851</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1126/science.1215904</pub-id><pub-id pub-id-type="pmid">22344443</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Ishiguro</surname><given-names>J</given-names></name><name><surname>Kitamura</surname><given-names>H</given-names></name><name><surname>Arima</surname><given-names>N</given-names></name><name><surname>Okutani</surname><given-names>M</given-names></name><name><surname>Shuto</surname><given-names>A</given-names></name><name><surname>Higashiyama</surname><given-names>S</given-names></name><name><surname>Ohwada</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Makide</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TGFα shedding assay: an accurate and versatile method for detecting GPCR activation</article-title><source>Nature Methods</source><volume>9</volume><fpage>1021</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2172</pub-id><pub-id pub-id-type="pmid">22983457</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenne</surname><given-names>CN</given-names></name><name><surname>Enders</surname><given-names>A</given-names></name><name><surname>Rivera</surname><given-names>R</given-names></name><name><surname>Watson</surname><given-names>SR</given-names></name><name><surname>Bankovich</surname><given-names>AJ</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Roots</surname><given-names>CM</given-names></name><name><surname>Beilke</surname><given-names>JN</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Reiner</surname><given-names>SL</given-names></name><name><surname>Miller</surname><given-names>SA</given-names></name><name><surname>Weinmann</surname><given-names>AS</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>2469</fpage><lpage>2481</lpage><pub-id pub-id-type="doi">10.1084/jem.20090525</pub-id><pub-id pub-id-type="pmid">19808259</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Radue</surname><given-names>E-W</given-names></name><name><surname>O’Connor</surname><given-names>P</given-names></name><name><surname>Polman</surname><given-names>C</given-names></name><name><surname>Hohlfeld</surname><given-names>R</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Selmaj</surname><given-names>K</given-names></name><name><surname>Agoropoulou</surname><given-names>C</given-names></name><name><surname>Leyk</surname><given-names>M</given-names></name><name><surname>Zhang-Auberson</surname><given-names>L</given-names></name><name><surname>Burtin</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis</article-title><source>New England Journal of Medicine</source><volume>362</volume><fpage>387</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0909494</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>MY</given-names></name><name><surname>Hayashizaki</surname><given-names>K</given-names></name><name><surname>Tokoyoda</surname><given-names>K</given-names></name><name><surname>Takamura</surname><given-names>S</given-names></name><name><surname>Motohashi</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Crucial role for CD69 in allergic inflammatory responses: CD69-myl9 system in the pathogenesis of airway inflammation</article-title><source>Immunological Reviews</source><volume>278</volume><fpage>87</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1111/imr.12559</pub-id><pub-id pub-id-type="pmid">28658550</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laidlaw</surname><given-names>BJ</given-names></name><name><surname>Gray</surname><given-names>EE</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ramírez-Valle</surname><given-names>F</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sphingosine-1-Phosphate receptor 2 restrains egress of γδ T cells from the skin</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>1487</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1084/jem.20190114</pub-id><pub-id pub-id-type="pmid">31160320</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y-L</given-names></name><name><surname>Khoshouei</surname><given-names>M</given-names></name><name><surname>Deganutti</surname><given-names>G</given-names></name><name><surname>Glukhova</surname><given-names>A</given-names></name><name><surname>Koole</surname><given-names>C</given-names></name><name><surname>Peat</surname><given-names>TS</given-names></name><name><surname>Radjainia</surname><given-names>M</given-names></name><name><surname>Plitzko</surname><given-names>JM</given-names></name><name><surname>Baumeister</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>LJ</given-names></name><name><surname>Hay</surname><given-names>DL</given-names></name><name><surname>Christopoulos</surname><given-names>A</given-names></name><name><surname>Reynolds</surname><given-names>CA</given-names></name><name><surname>Wootten</surname><given-names>D</given-names></name><name><surname>Sexton</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cryo-Em structure of the active, Gs-protein complexed, human CGRP receptor</article-title><source>Nature</source><volume>561</volume><fpage>492</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0535-y</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Paknejad</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Kihara</surname><given-names>Y</given-names></name><name><surname>Ray</surname><given-names>M</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Hite</surname><given-names>RK</given-names></name><name><surname>Huang</surname><given-names>XY</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>731</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28417-2</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>E</given-names></name><name><surname>Wolfreys</surname><given-names>FD</given-names></name><name><surname>Muppidi</surname><given-names>JR</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>S-geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8</article-title><source>Nature</source><volume>567</volume><fpage>244</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1003-z</pub-id><pub-id pub-id-type="pmid">30842656</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Koehl</surname><given-names>A</given-names></name><name><surname>Matile</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Hilger</surname><given-names>D</given-names></name><name><surname>Schertler</surname><given-names>GFX</given-names></name><name><surname>Manglik</surname><given-names>A</given-names></name><name><surname>Skiniotis</surname><given-names>G</given-names></name><name><surname>Dawson</surname><given-names>RJP</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Development of an antibody fragment that stabilizes GPCR/G-protein complexes</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3712</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06002-w</pub-id><pub-id pub-id-type="pmid">30213947</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>D-D</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>L-N</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-Em structures of inactive and active GABAB receptor</article-title><source>Cell Research</source><volume>30</volume><fpage>564</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0350-5</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Serasinghe</surname><given-names>M</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>J</given-names></name><name><surname>Chaluvadi</surname><given-names>VS</given-names></name><name><surname>Dustin</surname><given-names>ML</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Chipuk</surname><given-names>JE</given-names></name><name><surname>Schwab</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Lymphatic endothelial S1P promotes mitochondrial function and survival in naive T cells</article-title><source>Nature</source><volume>546</volume><fpage>158</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/nature22352</pub-id><pub-id pub-id-type="pmid">28538737</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moo</surname><given-names>EV</given-names></name><name><surname>van Senten</surname><given-names>JR</given-names></name><name><surname>Bräuner-Osborne</surname><given-names>H</given-names></name><name><surname>Møller</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Arrestin-Dependent and -independent internalization of G protein-coupled receptors: methods, mechanisms, and implications on cell signaling</article-title><source>Molecular Pharmacology</source><volume>99</volume><fpage>242</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1124/molpharm.120.000192</pub-id><pub-id pub-id-type="pmid">33472843</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales-Perez</surname><given-names>CL</given-names></name><name><surname>Noviello</surname><given-names>CM</given-names></name><name><surname>Hibbs</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Manipulation of subunit stoichiometry in heteromeric membrane proteins</article-title><source>Structure</source><volume>24</volume><fpage>797</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/j.str.2016.03.004</pub-id><pub-id pub-id-type="pmid">27041595</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriyama</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Green</surname><given-names>JA</given-names></name><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Okada</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Sphingosine-1-phosphate receptor 2 is critical for follicular helper T cell retention in germinal centers</article-title><source>The Journal of Experimental Medicine</source><volume>211</volume><fpage>1297</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1084/jem.20131666</pub-id><pub-id pub-id-type="pmid">24913235</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Kasprowicz</surname><given-names>DJ</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Schubert</surname><given-names>LA</given-names></name><name><surname>Gillard</surname><given-names>G</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Didierlaurent</surname><given-names>A</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Ziegler</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression</article-title><source>Journal of Immunology</source><volume>168</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.1.87</pub-id><pub-id pub-id-type="pmid">11751950</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niwa</surname><given-names>H</given-names></name><name><surname>Yamamura</surname><given-names>K</given-names></name><name><surname>Miyazaki</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Efficient selection for high-expression transfectants with a novel eukaryotic vector</article-title><source>Gene</source><volume>108</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(91)90434-d</pub-id><pub-id pub-id-type="pmid">1660837</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oo</surname><given-names>ML</given-names></name><name><surname>Thangada</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>MT</given-names></name><name><surname>Liu</surname><given-names>CH</given-names></name><name><surname>Macdonald</surname><given-names>TL</given-names></name><name><surname>Lynch</surname><given-names>KR</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>9082</fpage><lpage>9089</lpage><pub-id pub-id-type="doi">10.1074/jbc.M610318200</pub-id><pub-id pub-id-type="pmid">17237497</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappu</surname><given-names>R</given-names></name><name><surname>Schwab</surname><given-names>SR</given-names></name><name><surname>Cornelissen</surname><given-names>I</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name><name><surname>Regard</surname><given-names>JB</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Camerer</surname><given-names>E</given-names></name><name><surname>Zheng</surname><given-names>Y-W</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Coughlin</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate</article-title><source>Science</source><volume>316</volume><fpage>295</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1126/science.1139221</pub-id><pub-id pub-id-type="pmid">17363629</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>UCSF chimerax: structure visualization for researchers, educators, and developers</article-title><source>Protein Science</source><volume>30</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/pro.3943</pub-id><pub-id pub-id-type="pmid">32881101</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname><given-names>A</given-names></name><name><surname>Rubinstein</surname><given-names>JL</given-names></name><name><surname>Fleet</surname><given-names>DJ</given-names></name><name><surname>Brubaker</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination</article-title><source>Nature Methods</source><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id><pub-id pub-id-type="pmid">28165473</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>PM</given-names></name><name><surname>Kang</surname><given-names>YL</given-names></name><name><surname>Kirchhausen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endocytosis of ligand-activated sphingosine 1-phosphate receptor 1 mediated by the clathrin-pathway</article-title><source>Traffic</source><volume>17</volume><fpage>40</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1111/tra.12343</pub-id><pub-id pub-id-type="pmid">26481905</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohou</surname><given-names>A</given-names></name><name><surname>Grigorieff</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CTFFIND4: fast and accurate defocus estimation from electron micrographs</article-title><source>Journal of Structural Biology</source><volume>192</volume><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2015.08.008</pub-id><pub-id pub-id-type="pmid">26278980</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>H</given-names></name><name><surname>Stevens</surname><given-names>RC</given-names></name><name><surname>Hanson</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>E</given-names></name><name><surname>Oldstone</surname><given-names>MBA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sphingosine-1-Phosphate and its receptors: structure, signaling, and influence</article-title><source>Annual Review of Biochemistry</source><volume>82</volume><fpage>637</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-062411-130916</pub-id><pub-id pub-id-type="pmid">23527695</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>FA</given-names></name><name><surname>King</surname><given-names>R</given-names></name><name><surname>Smillie</surname><given-names>SJ</given-names></name><name><surname>Kodji</surname><given-names>X</given-names></name><name><surname>Brain</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Calcitonin gene-related peptide: physiology and pathophysiology</article-title><source>Physiological Reviews</source><volume>94</volume><fpage>1099</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1152/physrev.00034.2013</pub-id><pub-id pub-id-type="pmid">25287861</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>J-Y</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>SR</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name><name><surname>Matloubian</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients</article-title><source>Science</source><volume>309</volume><fpage>1735</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1126/science.1113640</pub-id><pub-id pub-id-type="pmid">16151014</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiow</surname><given-names>LR</given-names></name><name><surname>Rosen</surname><given-names>DB</given-names></name><name><surname>Brdicková</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name><name><surname>Matloubian</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cd69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs</article-title><source>Nature</source><volume>440</volume><fpage>540</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/nature04606</pub-id><pub-id pub-id-type="pmid">16525420</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegel</surname><given-names>S</given-names></name><name><surname>Milstien</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Sphingosine-1-Phosphate: an enigmatic signalling lipid</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>4</volume><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1038/nrm1103</pub-id><pub-id pub-id-type="pmid">12728273</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegel</surname><given-names>S</given-names></name><name><surname>Maczis</surname><given-names>MA</given-names></name><name><surname>Maceyka</surname><given-names>M</given-names></name><name><surname>Milstien</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>New insights into functions of the sphingosine-1-phosphate transporter SPNS2</article-title><source>Journal of Lipid Research</source><volume>60</volume><fpage>484</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1194/jlr.S091959</pub-id><pub-id pub-id-type="pmid">30655317</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velazhahan</surname><given-names>V</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Pándy-Szekeres</surname><given-names>G</given-names></name><name><surname>Kooistra</surname><given-names>AJ</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Gloriam</surname><given-names>DE</given-names></name><name><surname>Vaidehi</surname><given-names>N</given-names></name><name><surname>Tate</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structure of the class D GPCR Ste2 dimer coupled to two G proteins</article-title><source>Nature</source><volume>589</volume><fpage>148</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2994-1</pub-id><pub-id pub-id-type="pmid">33268889</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>T</given-names></name><name><surname>Merino</surname><given-names>F</given-names></name><name><surname>Stabrin</surname><given-names>M</given-names></name><name><surname>Moriya</surname><given-names>T</given-names></name><name><surname>Antoni</surname><given-names>C</given-names></name><name><surname>Apelbaum</surname><given-names>A</given-names></name><name><surname>Hagel</surname><given-names>P</given-names></name><name><surname>Sitsel</surname><given-names>O</given-names></name><name><surname>Raisch</surname><given-names>T</given-names></name><name><surname>Prumbaum</surname><given-names>D</given-names></name><name><surname>Quentin</surname><given-names>D</given-names></name><name><surname>Roderer</surname><given-names>D</given-names></name><name><surname>Tacke</surname><given-names>S</given-names></name><name><surname>Siebolds</surname><given-names>B</given-names></name><name><surname>Schubert</surname><given-names>E</given-names></name><name><surname>Shaikh</surname><given-names>TR</given-names></name><name><surname>Lill</surname><given-names>P</given-names></name><name><surname>Gatsogiannis</surname><given-names>C</given-names></name><name><surname>Raunser</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SPHIRE-cryolo is a fast and accurate fully automated particle picker for cryo-EM</article-title><source>Communications Biology</source><volume>2</volume><elocation-id>218</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-019-0437-z</pub-id><pub-id pub-id-type="pmid">31240256</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watterson</surname><given-names>KR</given-names></name><name><surname>Johnston</surname><given-names>E</given-names></name><name><surname>Chalmers</surname><given-names>C</given-names></name><name><surname>Pronin</surname><given-names>A</given-names></name><name><surname>Cook</surname><given-names>SJ</given-names></name><name><surname>Benovic</surname><given-names>JL</given-names></name><name><surname>Palmer</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Dual regulation of EDG1/S1P(1) receptor phosphorylation and internalization by protein kinase C and G-protein-coupled receptor kinase 2</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>5767</fpage><lpage>5777</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110647200</pub-id><pub-id pub-id-type="pmid">11741892</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>CJ</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Prisant</surname><given-names>MG</given-names></name><name><surname>Videau</surname><given-names>LL</given-names></name><name><surname>Deis</surname><given-names>LN</given-names></name><name><surname>Verma</surname><given-names>V</given-names></name><name><surname>Keedy</surname><given-names>DA</given-names></name><name><surname>Hintze</surname><given-names>BJ</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>SM</given-names></name><name><surname>Arendall</surname><given-names>WB</given-names></name><name><surname>Snoeyink</surname><given-names>J</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Lovell</surname><given-names>SC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MolProbity: more and better reference data for improved all-atom structure validation</article-title><source>Protein Science</source><volume>27</volume><fpage>293</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1002/pro.3330</pub-id><pub-id pub-id-type="pmid">29067766</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willinger</surname><given-names>T</given-names></name><name><surname>Ferguson</surname><given-names>SM</given-names></name><name><surname>Pereira</surname><given-names>JP</given-names></name><name><surname>De Camilli</surname><given-names>P</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dynamin 2-dependent endocytosis is required for sustained S1PR1 signaling</article-title><source>The Journal of Experimental Medicine</source><volume>211</volume><fpage>685</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1084/jem.20131343</pub-id><pub-id pub-id-type="pmid">24638168</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Ikuta</surname><given-names>T</given-names></name><name><surname>Kawakami</surname><given-names>K</given-names></name><name><surname>Kise</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>M-X</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Cai</surname><given-names>X-H</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism</article-title><source>Nature Chemical Biology</source><volume>18</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/s41589-021-00930-3</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1</article-title><source>Nature Chemical Biology</source><volume>18</volume><fpage>831</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1038/s41589-022-01038-y</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Gan</surname><given-names>B</given-names></name><name><surname>Ti</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ren</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural insights into sphingosine-1-phosphate receptor activation</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2117716119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2117716119</pub-id><pub-id pub-id-type="pmid">35412894</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structures of signaling complexes of lipid receptors s1pr1 and s1pr5 reveal mechanisms of activation and drug recognition</article-title><source>Cell Research</source><volume>31</volume><fpage>1263</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00566-x</pub-id><pub-id pub-id-type="pmid">34526663</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zachariah</surname><given-names>MA</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Neural crest-derived pericytes promote egress of mature thymocytes at the corticomedullary junction</article-title><source>Science</source><volume>328</volume><fpage>1129</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1126/science.1188222</pub-id><pub-id pub-id-type="pmid">20413455</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural insights into sphingosine-1-phosphate recognition and ligand selectivity of s1pr3-gi signaling complexes</article-title><source>Cell Research</source><volume>32</volume><fpage>218</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00567-w</pub-id><pub-id pub-id-type="pmid">34545189</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>SQ</given-names></name><name><surname>Palovcak</surname><given-names>E</given-names></name><name><surname>Armache</surname><given-names>JP</given-names></name><name><surname>Verba</surname><given-names>KA</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Agard</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy</article-title><source>Nature Methods</source><volume>14</volume><fpage>331</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4193</pub-id><pub-id pub-id-type="pmid">28250466</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>SF</given-names></name><name><surname>Ramsdell</surname><given-names>F</given-names></name><name><surname>Alderson</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The activation antigen CD69</article-title><source>Stem Cells</source><volume>12</volume><fpage>456</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1002/stem.5530120502</pub-id><pub-id pub-id-type="pmid">7804122</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zivanov</surname><given-names>J</given-names></name><name><surname>Nakane</surname><given-names>T</given-names></name><name><surname>Forsberg</surname><given-names>BO</given-names></name><name><surname>Kimanius</surname><given-names>D</given-names></name><name><surname>Hagen</surname><given-names>WJ</given-names></name><name><surname>Lindahl</surname><given-names>E</given-names></name><name><surname>Scheres</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>New tools for automated high-resolution cryo-EM structure determination in RELION-3</article-title><source>eLife</source><volume>7</volume><elocation-id>e42166</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.42166</pub-id><pub-id pub-id-type="pmid">30412051</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88204.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sohn</surname><given-names>Jungsan</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This important study provides unprecedented molecular insight into the activation and internalization of an important cell surface receptor induced by another membrane protein. The data supporting the conclusions are compelling, which include rigorous electron microscopy analysis, and biochemical and cell-based functional assays. The findings here not only reveal important mechanisms of S1P GPCR regulation, but also have implications for other fields such as receptor pharmacology and immunity.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88204.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sohn</surname><given-names>Jungsan</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Johns Hopkins University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Transmembrane protein CD69 acts as an S1PR1 agonist&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the assessment has been overseen by a Reviewing Editor and Tadatsugu Taniguchi as the Senior Editor.</p><p><italic>Reviewing Editor (Recommendations for the Authors):</italic></p><p>1. Please show densities for the key residues of the binding interface between CD69 and S1PR1 (Figure 2a and b), and the key residues relay the movement from TM4 to TM6 upon CD69 binding (Figure 3c)</p><p><italic>Reviewer #1 (Recommendations for the Authors):</italic></p><p>Chen et al. solve the structure of S1PR1/CD69/Gi protein complex by Cryo-EM. They show that a single helix of CD69 contacts the TM4 domain of S1PR1, maps the interacting sites and demonstrates the activation of Gi protein by this &quot;allosteric&quot; transmembrane modulator of S1PR1 GPCR. Their work suggests that CD69 activates S1PR1 in a manner independent of the ligand S1P, which is surprising and perhaps somewhat different than a previous publication (PMID: 20463015). Mutagenesis studies define important residues in both S1PR1 TM4 and CD69 for the association. Through the use of inhibitors for Gi and ß-arrestin, they suggest that CD69 induces S1PR1 internalization via the Gi pathway. They also address why CD69 is selective for S1PR1 vs. other S1PRs (i.e. S1PR2-5). By mutating 2 residues in the TM4 of one of the non-interacting GPCR (S1PR2), the authors demonstrate a partial association, suggesting that this approach may be useful in modulating other GPCRs.</p><p>The major strength of this work is the provision of a high-resolution (3.5 Ä) structure of S1PR1/CD69/Gi complex. This is important since it is the first structural description of the transmembrane GPCR modulator. Given that S1PR1 is an essential regulator of vascular development and lymphocyte trafficking, and that S1PR1 modulators are an important class of drugs for autoimmune diseases, the implications of this work are quite widespread. The work is rigorous and definitive and the manuscript is written in a lucid and scholarly manner.</p><p>There are some minor issues regarding detailed conclusions that the authors might want to address, either by discussion and/or provision of new experimental data to further increase the impact of the work.</p><p>Suggestions for further discussion and/or provision of new data:</p><p>1) The non-requirement for S1P in the GTPase assay and the structure is interesting and novel, especially since a previous influential publication on CD69/ S1PR1 interaction (PMID: 20463015) suggested that not to be the case. This should be further expounded.</p><p>2) In Figure 1 – since there is some basal GTP turnover even without the ligand, I wonder if there is some trace S1P in the cell system, even though the cells are maintained in charcoal/dextran-stripped FBS. Do the authors know if the media is indeed S1P null? Similarly, cells can make S1P via SPT pathway and activate the receptor. Again, this could be trace amounts since the palmitate concentration in stripped FBS is likely low. It would strengthen the authors' argument to measure S1P in cells and media.</p><p>3) Figure 4- The internalization data could be strengthened if the high-resolution images of cells are provided as an inset.</p><p>4) Can CD69 dimer accommodate 2 S1PR1 molecules in the absence of G proteins? Similarly, can CD69/ S1PR1 complex (either monomer or dimer) accommodate ß-arrestin? I am not suggesting the provision of actual data, but based on the structures, modeling can suggest whether steric hindrance can permit such a complex.</p><p><italic>Reviewer #2 (Recommendations for the Authors):</italic></p><p>This paper by Chen et al. reports the functional characterization of a membrane protein, CD69, as an agonist of the S1p1 receptor to induce receptor activation and internalization without lipid ligands. The authors further determined a cryo-electron microscopy (cryo-EM) structure of the human S1p1-Gi complex with CD69. The structure revealed how CD69 activates S1p1 by interacting with the transmembrane helix 4 (TM4) of S1p1. The structural findings are further validated by mutagenesis studies. The results provide a novel mechanism for the modulation of GPCR signaling by other membrane proteins.</p><p>The findings and conclusions of this paper are well supported by data. The cryo-EM structure determination looks solid. All functional assays were performed with appropriate replicates and controls. I would suggest addressing or clarifying the following issues:</p><p>1) Does CD69 just function as an agonist of S1p1 in vivo? What are other possible functional roles of CD69 involving its extracellular region? Does CD69 need to form a homodimer to activate S1p1?</p><p>2) The Gi-induced and b-arrestin-independent receptor internalization is interesting. What could be the molecular mechanism? Gi protein itself doesn't internalize upon activation.</p><p>The data are solid. The writing is good. All figures are clear and easy to understand. I don't have further suggestions for the authors.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88204.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewing Editor (Recommendations for the Authors):</p><p>1. Please show densities for the key residues of the binding interface between CD69 and S1PR1 (Figure 2a and b), and the key residues relay the movement from TM4 to TM6 upon CD69 binding (Figure 3c)</p></disp-quote><p>The density has been shown in Figure 1—figure supplement 2.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the Authors):</p><p>There are some minor issues regarding detailed conclusions that the authors might want to address, either by discussion and/or provision of new experimental data to further increase the impact of the work.</p><p>Suggestions for further discussion and/or provision of new data:</p><p>1) The non-requirement for S1P in the GTPase assay and the structure is interesting and novel, especially since a previous influential publication on CD69/ S1PR1 interaction (PMID: 20463015) suggested that not to be the case. This should be further expounded.</p></disp-quote><p>The cited publication (by Bankovich, Shiow and Cyster) found that CD69-S1PR1 co-expression in a cell line led to enhanced S1PR1 binding of radiolabeled S1P and proposed ‘these findings fit best with the interpretation that CD69 stabilizes a high affinity ligand binding conformation of S1PR1’. Our current finding that S1PR1 in complex with CD69 mirrors the S1P bound state of S1PR1 is entirely consistent with the earlier observations. We also note that the earlier study provided biochemical evidence that TM4 of S1PR1 was involved in the interaction with CD69, in accord with our structural findings.</p><disp-quote content-type="editor-comment"><p>2) In Figure 1 – since there is some basal GTP turnover even without the ligand, I wonder if there is some trace S1P in the cell system, even though the cells are maintained in charcoal/dextran-stripped FBS. Do the authors know if the media is indeed S1P null? Similarly, cells can make S1P via SPT pathway and activate the receptor. Again, this could be trace amounts since the palmitate concentration in stripped FBS is likely low. It would strengthen the authors' argument to measure S1P in cells and media.</p></disp-quote><p>We agree that the presence of low amounts of S1P in the culture is difficult to exclude. However, we know that under these culture conditions, S1PR1 is expressed on the cell surface (when expressed without CD69) and is downmodulated by the addition of exogenous S1P. This finding suggests that the receptor cannot be fully occupied by any S1P that could be available in the cultures.</p><disp-quote content-type="editor-comment"><p>3) Figure 4- The internalization data could be strengthened if the high-resolution images of cells are provided as an inset.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>4) Can CD69 dimer accommodate 2 S1PR1 molecules in the absence of G proteins? Similarly, can CD69/ S1PR1 complex (either monomer or dimer) accommodate ß-arrestin? I am not suggesting the provision of actual data, but based on the structures, modeling can suggest whether steric hindrance can permit such a complex.</p></disp-quote><p>Yes, we were able to purify a CD69-S1PR1 (2:2) complex without G proteins and determined its structure at a relatively low resolution (4.7 Å) (see <xref ref-type="fig" rid="sa2fig1">Author response image 1A</xref>). When superimposed to both S1PR1s in the CD69-S1PR1 (2:2) complex, the two β-arrestin 1 molecules from the NTSR1-βarrestin 1 complex (PMID 31945771) not only clash with each other but also collide with the other S1PR1 (<xref ref-type="fig" rid="sa2fig1">Author response image 1B</xref>). However, β-arrestin 1 rotates ~60° in the M2R-β-arrestin 1 structure (PMID 31945772) compared to that of NTSR1-βarrestin 1. With this orientation, the two protomers are compatible with each other when aligned to S1PR1 (<xref ref-type="fig" rid="sa2fig1">Author response image 1C</xref>). It will be interesting in future work to determine if the CD69-S1PR1 2:2 complex exists in cells and to test if it interacts with β-arrestins.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><p>(<bold>A</bold>) Cryo-EM structure of the 2:2 CD69-S1PR1 complex. (<bold>B</bold>) Superimposition of CD69-S1PR1 with NTSR1-β-arrestin 1 complex (6UP7). Clashes are indicated by dashed ovals. (<bold>C</bold>) Superimposition of CD69-S1PR1 with M2R-β-arrestin 1 complex (PDB: 6U1N).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88204-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the Authors):</p><p>This paper by Chen et al. reports the functional characterization of a membrane protein, CD69, as an agonist of the S1p1 receptor to induce receptor activation and internalization without lipid ligands. The authors further determined a cryo-electron microscopy (cryo-EM) structure of the human S1p1-Gi complex with CD69. The structure revealed how CD69 activates S1p1 by interacting with the transmembrane helix 4 (TM4) of S1p1. The structural findings are further validated by mutagenesis studies. The results provide a novel mechanism for the modulation of GPCR signaling by other membrane proteins.</p><p>The findings and conclusions of this paper are well supported by data. The cryo-EM structure determination looks solid. All functional assays were performed with appropriate replicates and controls. I would suggest addressing or clarifying the following issues:</p><p>1) Does CD69 just function as an agonist of S1p1 in vivo? What are other possible functional roles of CD69 involving its extracellular region? Does CD69 need to form a homodimer to activate S1p1?</p></disp-quote><p>As discussed in the manuscript, CD69 upregulation in lymphocytes is associated with rapid loss of S1PR1 function in promoting egress from tissues into blood or lymph. Prior work has shown that S1P gradients are critical for lymphocyte egress to occur. If S1P abundance is greatly increased in tissues (due to inhibition of its metabolism), lymphocyte egress is blocked. We suggest that by activating S1RPR1 in cis, CD69 causes lymphocytes to lose their ability to sense the egress promoting S1P gradient, thereby promoting their retention in tissues.</p><p>We did not detect any evidence for the CD69 ectodomain being involved in the interaction with S1PR1, consistent with earlier biochemical findings (PMID 20463015). Other work has suggested the CD69 ectodomain may interact with Galectin-1 and this may modulate T cell cytokine production; an interaction with the S100A8/S100A9 complex has also been suggested (reviewed in PMID 28475283). A further study provided evidence for CD69 interaction with extracellular myosin light chain (Myl) 9 and Myl12 to regulate T cell function in the inflamed lung (PMID 28783682). It will be of interest in future studies to understand whether molecules that interact with CD69 in trans can influence the internalization or signaling by the S1PR1-CD69 complex.</p><p>Like related C-type lectins, CD69 is believed to form a disulfide linked homodimer during synthesis in the endoplasmic reticulum. Therefore, while a monomer is predicted to be able to engage S1PR1, we don’t consider it likely that a monomeric form would be physiologically relevant.</p><disp-quote content-type="editor-comment"><p>2) The Gi-induced and β-arrestin-independent receptor internalization is interesting. What could be the molecular mechanism? Gi protein itself doesn't internalize upon activation.</p></disp-quote><p>We don’t yet know the mechanism. We note in the manuscript that GRK2 and dynamin have been shown to participate in S1PR1 internalization in response to S1P, and that these factors promote internalization of some receptors independently of β-arrestins. Future studies will need to test whether these or other molecules are involved.</p></body></sub-article></article>